Skip to main content

Table 4 Occurrence rate of bleeding (safety endpoint)

From: Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery

Bleeding events

Rivaroxaban group

Parnaparin group

P value

Any bleeding during the treatment

21 (6.2 %)

17 (5.2 %)

>0.5

Severe bleeding

2 (0.6 %)

1 (0.3 %)

>0.25*

Fatal bleeding

0

0

 

Bleeding into important organs

1

0

 

Reoccurrence of surgical bleeding

1

0

 

Clinically obvious bleeding outside the surgical site

0

1

 

Induced hemoglobin decreasing

0

0

 

Induced blood transfusion ≥2 units

0

0

 

Non-severe bleeding

19 (5.6 %)

16 (4.9 %)

>0.5

Clinically related non-severe bleedinga

6

6

 

Bleeding incision complicationsb

7

4

 

Other non-severe bleeding

6

6

 
  1. *Used Fisher’s exact test
  2. aClinically related non-severe bleeding included multi-sites bleeding, spontaneous hematoma and big incision hematoma
  3. bBleeding incision complications was the combined indicator of big incision bleeding and surgical site bleeding